Literature DB >> 12938867

The diverse roles of anticonvulsants in bipolar disorders.

Terence A Ketter1, Po W Wang, Olga V Becker, Cecylia Nowakowska, Yen-Shou Yang.   

Abstract

Anticonvulsant drugs (ACs) have diverse antiseizure, psychotropic, and biochemical effects. Carbamazepine and valproate have mood-stabilizing actions, benzodiazepines and gabapentin have anxiolytic actions, lamotrigine is useful in rapid cycling and acute treatment and prophylaxis of bipolar depression, and topiramate and zonisamide can yield weight loss. Limited controlled data suggest the carbamazepine keto derivative oxcarbazepine has antimanic effects. A categorical approach to the diverse roles of ACs in bipolar disorders is proposed, using broad categories of ACs, on the basis of their predominant psychotropic profiles. Thus, some ACs have "sedating" profiles that may include sedation, cognitive difficulties, fatigue, weight gain, and possibly antimanic and/or anxiolytic effects. In contrast, some newer ACs have "activating" profiles that may include improved energy, weight loss, and possibly antidepressant and even anxiogenic effects. Still other newer ACs have novel "mixed" profiles, combining sedation and weight loss. A categorical-mechanistic extension of this approach is also presented, with hypotheses that "sedating" profiles might be related to prominent potentiation of gamma-aminobutyric acid (GABA) inhibitory neurotransmission, "activating" profiles could be related to prominent attenuation of glutamate excitatory neurotransmission, and for "mixed" profiles, sedation and weight loss might be related to concurrent GABAergic and antiglutamatergic actions, respectively. The categorical approach may have utility as an aid to clinicians in reinforcing the heterogeneity ACs, and recalling psychotropic profiles of individual ACs, but is limited as it fails to address the etiology of the heterogeneity of AC psychotropic effects. The categorical-mechanistic extension strives to address this issue, but requires systematic clinical investigation of more precise relationships between psychotropic profiles and discrete mechanisms of action to assess its merits.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12938867     DOI: 10.1023/a:1024636309185

Source DB:  PubMed          Journal:  Ann Clin Psychiatry        ISSN: 1040-1237            Impact factor:   1.567


  5 in total

1.  Topiramate raises anterior cingulate cortex glutamine levels in healthy men; a 4.0 T magnetic resonance spectroscopy study.

Authors:  Constance M Moore; Megan Wardrop; Blaise deB Frederick; Perry F Renshaw
Journal:  Psychopharmacology (Berl)       Date:  2006-08-31       Impact factor: 4.530

2.  Glutamine and glutamate levels in children and adolescents with bipolar disorder: a 4.0-T proton magnetic resonance spectroscopy study of the anterior cingulate cortex.

Authors:  Constance M Moore; Jean A Frazier; Carol A Glod; Janis L Breeze; Megan Dieterich; Chelsea T Finn; Blaise deB Frederick; Perry F Renshaw
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2007-04       Impact factor: 8.829

3.  Characterization of the gut microbiota among Veterans with unique military-related exposures and high prevalence of chronic health conditions: A United States-Veteran Microbiome Project (US-VMP) study.

Authors:  Maggie A Stanislawski; Christopher E Stamper; Kelly A Stearns-Yoder; Andrew J Hoisington; Diana P Brostow; Jeri E Forster; Teodor T Postolache; Christopher A Lowry; Lisa A Brenner
Journal:  Brain Behav Immun Health       Date:  2021-09-14

4.  Psychopharmacology of topiramate: from epilepsy to bipolar disorder.

Authors:  Marco Mula; Andrea E Cavanna; Francesco Monaco
Journal:  Neuropsychiatr Dis Treat       Date:  2006-12       Impact factor: 2.570

5.  Combining an SSRI with an anticonvulsant in depressed patients with dysphoric mood: an open study.

Authors:  Massimo Pasquini; Angelo Picardi; Azzurra Speca; Valerio Orlandi; Lorenzo Tarsitani; Pierluigi Morosini; Isabella Cascavilla; Massimo Biondi
Journal:  Clin Pract Epidemiol Ment Health       Date:  2007-02-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.